Evidence, in the open.
From protocol to site list, on one evidence base
A sponsor’s world-class experts could agree on the science, but not on the number the whole program hinged on: how many patients would actually qualify? We could answer it — and the final protocol qualified nearly three times the patients of the draft, then became a ranked list of the sites that can actually reach them.
Read the case study →The Cost of Guessing: what a wrong site really costs
The screening haircut, the amendment tax, the rescue sites, the dropout leak — the hidden bill for choosing sites on intuition instead of evidence, added up.
Coming soonThey guess. We count.
Most site-selection tools infer where patients probably are from a partial sample. We count the actual patients, across every institution — and why that difference decides a rare-disease trial.
Coming soonIntroducing the AI Founding Partner Program
A feasibility engine built inside your own cloud, trained on your data, seen by no one. A small number of Founding Partner slots for CROs who run feasibility at scale.
Coming soonThe lead story above is our latest in this section — more is on the way.
Let’s talk about your study.
We will show you where the patients are and which sites will perform — the evidence you walk into the bid defense with.